



Gp 11653/18

PATENT

RECEIVED

NOV 21 2002

TECH CENTER 1600/2900

P#17

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re Application of:**

Hateboer et al.

**Serial No.:** 09/549,463

**Filed:** April 14, 2000

**For:** RECOMBINANT PROTEIN  
PRODUCTION IN A HUMAN CELL

**Confirmation No.:** 8657

**Examiner:** R. Mitra

**Group Art Unit:** 1653

**Attorney Docket No.:** 2183-4038.1US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

November 13, 2002  
Date

*Betty Vowles*  
Signature

Betty Vowles  
Name (Type Print)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.



Serial No.: 09/549,463

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US - 5,994,128	11-30-1999	Fallaux et al.

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
WO 93/03163	02-18-1993	Fond Nat Transfusion
WO 97/00326	01-03-1997	Univ Leiden
WO 95/29994	11-09-1995	Univ Michigan
EP 0 185 573	06-25-1986	Pasteur Institut

Other Documents

PCT International Search Report, PCT/NL00/00247, dated October 9, 2000, 3 pages.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56 & 1.175, applicant hereby identifies the following listed copending applications naming the same inventor(s):

Attorney Docket No.: 2578-3840US  
Serial No.: 09/065,752  
Filing Date: 4/24/1998  
Title: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT  
ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.: 2887-3836US  
Serial No.: 09/097,239  
Filing Date: 6/12/1998  
Title: HIGH THROUGHPUT SCREENING OF GENE FUNCTION  
USING ADENOVIRAL LIBRARIES FOR FUNCTIONAL  
GENOMICS APPLICATIONS

Attorney Docket No.: 2183-4230US  
Serial No.: 09/214,836  
Filing Date: 10/4/1999  
Title: MELANOMA ASSOCIATED PEPTIDE ANALOGUES AND  
VACCINES AGAINST MELANOMA

Attorney Docket No.: 2183-4075US  
Serial No.: 09/332,803  
Filing Date: 6/14/1999  
Title: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT  
ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.: 2578-4123.2US  
Serial No.: 09/348,354  
Filing Date: 7/7/1999  
Title: CHIMAERIC ADENOVIRUSES

Attorney Docket No.: 2183-4231US  
Serial No.: 09/444,284  
Filing Date: 11/19/1999  
Title: GENE DELIVERY VECTORS PROVIDED WITH A TISSUE  
TROPISM FOR SMOOTH MUSCLE CELLS, AND/OR  
ENDOTHELIAL CELLS

Attorney Docket No.: 2183-4240US  
Serial No.: 09/449,854  
Filing Date: 11/26/1999  
Title: PRODUCTION OF VACCINES

Attorney Docket No.: 2183-4215US  
Serial No.: 09/481,201  
Filing Date: 1/11/2000  
Title: INTERLEUKIN-3 GENE THERAPY FOR CANCER

Attorney Docket No.: 2183-4318US  
Serial No.: 09/502,624  
Filing Date: 2/11/2000  
Title: VECTORS AND METHODS FOR PROVIDING CELLS WITH  
ADDITIONAL NUCLEIC ACID MATERIAL INTEGRATED IN  
THE GENOME OF SAID CELLS

Attorney Docket No.: 2578-3833.3US  
Serial No.: 09/506,548  
Filing Date: 2/16/2000  
Title: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT  
ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.: 2183-3982.2US  
Serial No.: 09/517,898  
Filing Date: 3/3/2000  
Title: MEANS AND METHODS FOR FIBROBLAST-LIKE OR  
MACROPHAGE-LIKE CELL TRANSDUCTION

Attorney Docket No.: 2183-4070.1US  
Serial No.: 09/573,740  
Filing Date: 5/18/2000  
Title: SEROTYPES OF ADENOVIRUS AND USES THEREOF

Attorney Docket No.: 2183-4497US  
Serial No.: 09/621,593  
Filing Date: 7/21/2000  
Title: MEANS AND METHODS FOR RAISING ANTIBODY  
CONCENTRATION IN COMPARTMENTS OF THE BODY OF A  
NON HUMAN ANIMAL

Attorney Docket No.: 2183-4192.1US  
Serial No.: 09/657,492  
Filing Date: 9/8/2000  
Title: MODIFIED ADENOVIRAL VECTORS FOR USE IN GENE  
THERAPY

Attorney Docket No.: 2578-4489US  
Serial No.: 09/665,472  
Filing Date: 9/20/2000  
Title: GENE DELIVERY VECTORS PROVIDED WITH A TISSUE  
TROPISM FOR DENDRITIC CELLS

Attorney Docket No.: 2183-4626US  
Serial No.: 09/722,867  
Filing Date: 11/27/2000  
Title: PRODUCTION OF VACCINES

Attorney Docket No.: 2183-4843US  
Serial No.: 09/843,894  
Filing Date: 4/27/2001  
Title: AAV VECTOR PRODUCTION

Attorney Docket No.: 2578-3840.1US  
Serial No.: 09/900,062  
Filing Date: 7/6/2001  
Title: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT  
ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.: 2578-3935.1US  
Serial No.: 09/912,552  
Filing Date: 7/23/2001  
Title: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT  
ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.: 2578-3833.5US  
Serial No.: 09/918,029  
Filing Date: 7/30/2001  
Title: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT  
ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.: 2578-4509.1US  
Serial No.: 09/928,262  
Filing Date: 8/10/2001  
Title: GENE DELIVERY VECTORS WITH CELL TYPE SPECIFICITY  
FOR PRIMARY HUMAN CHONDROCYTES

Attorney Docket No.: 2578-4123.1US  
Serial No.: 09/953,280  
Filing Date: 9/14/2001  
Title: CHIMAERIC ADENOVIRUSES

Attorney Docket No.: 2183-5006.1US  
Serial No.: 10/010,645  
Filing Date: 11/13/2001  
Title: GENE DELIVERY VECTORS WITH CELL TYPE SPECIFICITY  
FOR MESENCHYMAL STEM CELLS

Attorney Docket No.: 2578-3833.6US  
Serial No.: 10/038,271  
Filing Date: 10/23/2001  
Title: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT  
ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.: 2578-3833.7US  
Serial No.: 10/125,751  
Filing Date: 4/18/2002  
Title: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT  
ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.: 2578-3955.1US  
Serial No.: 10/136,139  
Filing Date: 5/1/2002  
Title: MEANS AND METHODS FOR NUCLEIC ACID DELIVERY  
VEHICLE DESIGN AND NUCLEIC ACID TRANSFER

Attorney Docket No.: 2578-4451.1US  
Serial No.: 10/196,688  
Filing Date: 7/15/2002  
Title: ADENO-ASSOCIATED VIRUS AND ADENOVIRUS CHIMERIC  
RECOMBINANT VIRUSES USEFUL FOR THE INTEGRATION  
OF FOREIGN GENETIC INFORMATION INTO  
CHROMOSOMAL DNA OF TARGET CELLS

Attorney Docket No.: 2578-3833.8US  
Serial No.: 10/219,414  
Filing Date: 8/15/2002  
Title: STOCKS OF REPLICATION DEFICIENT ADENOVIRUS

Attorney Docket No.: 2578-4215.1US  
Serial No.: 10/231,735  
Filing Date: 8/28/2002  
Title: INTERLEUKIN-3 GENE THERAPY FOR CANCER


Attorney Docket No.: 2578-4038.2US  
Serial No.: 10/234,007  
Filing Date: 9/3/2002  
Title: RECOMBINANT PROTEIN PRODUCTION IN A HUMAN CELL

Serial No.: 09/549,463

This Information Disclosure Statement is filed after the mailing date of a first Office Action on the merits.

The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

Respectfully submitted,



Allen C. Turner

Registration No. 33,041

Attorney for Applicant(s)

TRASKBRITT, PC

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: November 13, 2002

ACT/bv

Enclosures: Form PTO-1449 or PTO/SB/08

Cited Documents

Document in ProLaw

NOV 18 2002

P10 SB 08A (10-01)

Approved for use through 10-31-2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A PIO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

*Complete if Known*

Application Number	09/549,463	<div>RECEIVED</div> <div>NOV 21 2009</div> <div>TECH CENTER 10</div>
Filing Date	April 14, 2000	
First Named Inventor	Hateboer et al.	
Group Art Unit	1653	
Examiner Name	R. Mitra	
Attorney Docket Number	2183-4038.1US	

RECEIVED

NOV 21 2002

**TECH CENTER 1800/2900**

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>†</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>n</sup>
		Country Code* - Number* - Kind Code* ( <i>if known</i> )				
		WO 93 03163	02-18-1993	Fond Nat Transfusion		
		WO 97/00326	01-03-1997	Univ Leiden		
		WO 95/29994	11-09-1995	Univ Michigan		
		EP 0 185 573	06-25-1986	Pasteur Institut		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov/MPEP/901.04](http://www.uspto.gov/MPEP/901.04). <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard S1.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard S1.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**Burden Hour Statement** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231



